Which bone graft is best? That is usually the wrong question.
The more useful questions are these: which biological and mechanical properties does this particular defect require, does the proposed graft actually supply them, how strong is the evidence behind that claim, and what safety burden comes with it?
Safety and Effectiveness Profiles of Bone Grafts and Bone Graft Substitutes offers a practical, evidence-based framework for answering those questions. Written by physician-scientist and medical-device safety expert Dr. Hafez Selim, with a foreword by Dr. Mohamed Attawia, it integrates bone biology, biomaterials science, clinical evidence, product safety, regulatory pathways, and real-world implementation into a single reference.
The book profiles the full range of materials in clinical use ? autograft and allograft, demineralized bone matrix, cellular bone matrices, xenograft, calcium-phosphate ceramics and cements, bioactive glass, synthetic composites, bone morphogenetic proteins, platelet-derived growth factor products, P-15 peptides, marrow concentrates, and platelet-based therapies ? and examines how each performs across spine surgery, fracture and nonunion care, segmental defects, foot and ankle procedures, dental and maxillofacial grafting, oncologic reconstruction, infected fields, and special populations.
Throughout, effectiveness and safety are treated as a single subject. Dr. Selim sets out structured methods for appraising clinical evidence alongside adverse effects, donor-transmission risk, traceability, recalls, and post-market safety signals, and explains the United States and European regulatory pathways in enough detail to show why regulatory authorization should never be mistaken for clinical proof. Worked clinical vignettes, selection algorithms, comparison tables, and an interactive companion tool carry that analysis through to decisions at the point of care, while chapters on patient optimization, shared decision-making, procurement, operating-room handling, documentation, and institutional product review address the work that surrounds the choice itself.
Rather than treating every product within a material class as interchangeable, the book insists on the particulars that determine outcome: exact formulation, processing, dose, carrier, indication, comparator, and clinical endpoint. It is equally clear about where the evidence is strong, where extrapolation is inappropriate, and where uncertainty has to be communicated honestly.
It is written for orthopaedic, spine, foot-and-ankle, dental, and maxillofacial clinicians and trainees, and for the biomaterials scientists, product-development engineers, medical safety and regulatory professionals, researchers, and hospital value-analysis teams who evaluate, develop, purchase, monitor, or regulate these materials.
Evidence reviewed through August 2, 2026.
